What must an ipamorelin CoA confirm for Aib-pentapeptide identity?
A research CoA for ipamorelin should confirm a single chemical entity, not a catalogue synonym. The structure expected by laboratories is the amidated pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, in which 2-aminoisobutyric acid occupies the N-terminus, histidine is followed by D-2-naphthylalanine and D-phenylalanine, and the C-terminus is lysinamide rather than a free carboxylic acid. Those non-proteinogenic residues are identity-critical: a certificate that lists only a generic peptide purity percentage has not identified ipamorelin.
Raun and co-workers described ipamorelin as a pentapeptide growth hormone secretagogue, which is why catalogues treat the name as a defined chemical-class member rather than a blend (PMID:9849822). Lot documents must still state sequence, stereochemical descriptors, molecular formula and a theoretical mass for the free peptide. The formula commonly associated with the unmodified amidated sequence is C38H49N9O5; a different formula should be resolved as counterion, hydrate, truncation or a different analogue.
Matsumoto and colleagues examined structural similarity between ghrelin derivatives and peptidyl growth hormone secretagogues (PMID:11396951). Invoices therefore sometimes substitute a class name such as GHS, GHRP or ghrelin mimetic for the ipamorelin sequence. Class names are not identity. A specification should require the five-residue sequence with Aib, D-2-Nal, D-Phe and C-terminal amide written out, and the same lot number on the vial label.
Intact mass cannot assign D- versus L-configuration, and routine amino-acid analysis may not quantify Aib or D-2-Nal. Chromatographic retention against a documented method, paired with a mass match, is the minimum orthogonal identity pair. Appearance as a lyophilised solid, labelled mass and salt form belong on the same certificate so later net-peptide-content calculations use the correct counterion.
How should HPLC purity and related-substance fields be read before you buy?
Reversed-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet detection remains the purity method most often attached to research-peptide CoAs. For ipamorelin, laboratories should expect a C18 or equivalent alkyl-bonded column, a water-acetonitrile gradient acidified with trifluoroacetic acid or formic acid, and detection near 214-220 nm, where the peptide bond absorbs. Those parameters are not universal; they must be printed on the CoA or method sheet so a purity percentage can be interpreted.
Read the purity figure as an area-normalised chromatographic result unless the certificate explicitly states an assay. Area-percent purity is the main-peak area divided by the sum of integrated peak areas above a reporting threshold. It is not net peptide content and it is not a mass-balance assay. If the integrator includes the solvent front, gradient artefacts or a blank peak, the purity number is inflated. A high reporting threshold can hide related substances. The CoA should state the ignore limit, the integration wavelength, and whether peaks below that limit were discarded.
A usable related-substance table lists relative retention time or retention time, area percent, and, where known, a peak assignment such as a deletion sequence, truncated peptide or diastereomer. Unidentified peaks above the threshold should still be listed. System-suitability data—blank, tailing factor, theoretical plates and resolution—show whether the method was in control.
Diode-array peak-purity indices can flag co-elution when a ratiogram or purity angle is reported, but they do not identify the main component. For a pentapeptide carrying two D-residues, diastereomeric impurities are a realistic related-substance class. Laboratories comparing suppliers should request the chromatogram PDF, the peak table and the method conditions as one pack, and should reject a purity claim that cannot be reconciled with those files. HPLC purity answers how much of the integrated ultraviolet response sits in the main peak; it does not answer whether that peak is ipamorelin.
Why do orthogonal mass spectra matter for Aib-pentapeptide identity?
Electrospray ionisation mass spectrometry (ESI-MS) is the usual orthogonal identity method on peptide CoAs. For a molecule near 700 Da, laboratories typically look for [M+H]+ and often [M+2H]2+, with the deconvoluted mass compared with the theoretical monoisotopic mass of the free amidated pentapeptide. Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry is an acceptable alternative for intact mass when the spectrum, matrix and mass error are reported. A statement that mass spectrometry confirms identity, without observed m/z values, charge states or a mass-error window, is not an analytical result.
Mass agreement is necessary and not sufficient. The D-Phe and D-2-Nal residues are isobaric with their L-enantiomers, and Aib placement is not proven by intact mass alone. Tandem mass spectrometry can supply sequence-informative fragment ions that support residue order. Few research CoAs include a fully assigned fragment table; when they do not, intact mass plus documented HPLC retention remains the practical pair, and stereochemistry stays untested.
Fowkes and co-workers described peptidomimetic growth hormone secretagogue derivatives prepared for positron emission tomography imaging of the ghrelin receptor (PMID:30282322). The procurement point is that a GHS-ligand label covers many scaffolds, so a mass spectrum must be tied to the ipamorelin sequence rather than to a receptor-class synonym. Ahnfelt-Ronne and colleagues discussed nomenclature connecting growth hormone-releasing peptides and ghrelin-pathway ligands (PMID:11322495). Catalogues that file ipamorelin under a GHRP heading create a documentation mismatch unless the CoA, invoice and vial use the same identifier.
Orthogonal reporting means the HPLC and MS files share lot number, sample identifier and analysis date. A recycled spectrum from another lot, or a theoretical mass with no observed ions, should be treated as missing data. The CoA must be complete enough that an independent LC-MS repeat would have a target mass and a target retention time.
Which lot-traceability checks separate a documented supplier from a catalogue listing?
Lot traceability is the ability to join every analytical file to one labelled container. The vial should carry a lot or batch number identical to the CoA header, the chromatogram header, the mass-spectrum header and any water-content or residual-solvent annex. If those strings differ, goods-in should quarantine the discrepancy before the material is logged as accepted research stock.
The CoA should state the date of manufacture or synthesis, the date of analysis, and a retest date used for laboratory inventory control of a research chemical. An analysis date long after manufacture without a supporting stability file does not by itself invalidate identity, but it should be recorded. Multi-vial orders should state whether vials share one lot; shared-lot orders should share one CoA pack, and mixed lots should not be covered by a single purity number.
Concordance checks that catch incomplete suppliers include: peak-area percent on the CoA matching the chromatogram main-peak table; the sample name on the HPLC sequence matching the vial identifier; detector wavelength on the method matching the chromatogram; and the theoretical mass on the CoA matching the observed MS ions. Keep the original PDF so a later revised certificate can be compared with the file received at dispatch.
Australian procurement adds a documentary logistics layer: local stock reduces the chance that a substituted lot ships under the ordered CoA, and tracked dispatch provides an independent timestamp for chain of custody. Neither replaces HPLC-MS. A supplier who issues a batch-report pack per lot is documenting material; a supplier who issues a generic purity badge for a product name is documenting a catalogue. Receiving records should assign a unique goods-in number, list vial identifiers against the lot, and store the CoA pack with the inventory record so a later mismatch between a chromatogram and a retained vial can be investigated.
How do counterion, net peptide content and CoA packs change a purchase decision?
HPLC area-percent purity does not tell a laboratory how much of the labelled vial mass is ipamorelin peptide. Lyophilised research peptides are typically salts. Trifluoroacetate and acetate are the common counterions; each contributes mass that is not peptide. Water, residual organic solvents from purification, and related substances also occupy part of the labelled mass. Net peptide content is the fraction of the labelled mass that is the peptide itself, often estimated from nitrogen content, amino-acid analysis, or a combination of counterion assay, Karl Fischer water and chromatographic purity.
A CoA that omits counterion identity forces the laboratory to treat the labelled milligrams as an unknown mixture. Ion chromatography or fluorine nuclear magnetic resonance can quantify trifluoroacetate; acetate can be quantified by HPLC or ion chromatography. Karl Fischer titration reports water. Residual-solvent testing by headspace gas chromatography, where performed, belongs in the same pack. When a laboratory converts labelled vial mass into a solution concentration for an analytical standard, using HPLC purity alone will overestimate peptide concentration if the counterion load is high. That is a calibration error, not a biological statement.
Lots with the same area-percent purity can differ in net content if one is a trifluoroacetate salt with higher residual water and the other is an acetate salt. If net peptide content is absent, the lot may still be logged for qualitative identity work, but labelled milligrams should not be treated as a quantitative standard.
Evaluating the supplier then becomes a pack-completeness audit: lot-specific chromatogram PDFs rather than stock images; observed m/z values and charge states; related substances with relative retention times; named counterion; shared-lot disclosure on multi-vial orders; and a certificate issuer that matches the invoicing entity. ClaraScience supplies research peptides with batch documentation intended for laboratory quality systems. Material is supplied for laboratory research and analytical method work only and is not a registered medicine. The checklist in this article is chemistry, identity, purity, traceability and documentation. It is not a use recommendation and it does not address biological endpoints.
Order Ipamorelin with documentation
If this guide helped you evaluate Ipamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Ipamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What identity fields should appear on an ipamorelin certificate of analysis?
The CoA should list the sequence with stereochemistry (Aib-His-D-2-Nal-D-Phe-Lys-NH2), C-terminal amide, molecular formula, theoretical mass for the free peptide, salt form, and a lot number matching the vial. An orthogonal mass result with observed ions should sit in the same pack. A name-only certificate does not confirm pentapeptide identity.
Is HPLC area-percent purity enough to accept a research lot?
No. Area-percent purity describes the main-peak share of integrated ultraviolet response above a reporting threshold. It is not net peptide content and it is not structural identity. Request the chromatogram, peak table, method conditions and a mass match on the same lot before logging the material as accepted research stock.
Why can mass spectrometry agree and the lot still be the wrong stereoisomer?
D-Phe and D-2-Nal have the same mass as the corresponding L-enantiomers, and intact mass does not place Aib in the sequence. A mass match supports elemental composition within instrument error. Stereochemistry remains unproven unless a discriminating chromatographic method or another orthogonal test is documented on the same lot.
Which identifiers must match across the vial and the CoA pack?
The lot or batch number should be identical on the vial label, CoA header, chromatogram header and mass-spectrum header. Sample or vial identifiers on multi-vial orders should also reconcile. Mismatched strings are a quarantine event at goods-in, not a clerical detail to ignore after the material has been logged.
Why does the CoA need to name acetate or trifluoroacetate?
Counterion mass is not peptide mass. Two lots with the same HPLC purity can differ in net peptide content if salt form and water differ. Named counterion, water content and, where available, net peptide content allow labelled milligrams to be interpreted when preparing analytical solutions.
Does local Australian stock replace HPLC-MS documentation?
No. Local stock and tracked dispatch support inventory control and chain of custody. They do not identify the pentapeptide or measure related substances. Sequence, chromatogram, observed mass ions and lot concordance remain the acceptance pack regardless of warehouse location in Australia.
References
- PMID:9849822 — Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol — 1998
- PMID:11396951 — Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues — Biochem Biophys Res Commun — 2001
- PMID:30282322 — Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor — Eur J Med Chem — 2018
- PMID:11322495 — Do growth hormone-releasing peptides act as ghrelin secretagogues? — Endocrine — 2001
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
